• Users Online: 1260
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 40  |  Issue : 4  |  Page : 175-176

VTD in newly diagnosed myeloma: an institutional experience

Department of Hematology, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India

Correspondence Address:
Meet Kumar
DM (Clin Hematology), Department of Hematology, Nil Ratan Sircar Medical College and Hospital, Kolkata - 700 014, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1110-1067.170202

Rights and Permissions

Background Myeloma management has evolved over the years with logarithmic expansion of available treatment options. The treatment algorithms are also changing because of the better responses obtained with newer agents. Bortezomib, thalidomide and dexamathasone (also known as VTD) is one such therapy that has shown improved long term outcomes. Materials and methods We conducted a single-center, retrospective analysis of all myeloma patients treated with VTD chemotherapy. Results An overall response achieved was 85.7% with 40% CR. Conclusion We conclude VTD is an effective chemotherapy regimen in newly-diagnosed myeloma patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded168    
    Comments [Add]    

Recommend this journal